Giulia Marvaso: SBRT alone vs SBRT + 6 month ADT in oligorecurrent mHSPC

Barbara Jereczek-Fossa, Professor at Università degli Studi di Milano, reshared a post on LinkedIn by Giulia Marvaso, Assistant Professor at Università degli Studi di Milano, adding:

“Compliments to Giulia Marvaso and the whole RADIOSA IEO Team.

Our phase II randomized RADIOSA trial advances understanding of metastatic prostate cancer, showing that short (6 months) systemic therapy combined with metastasis-directed therapy is a winning approach.

Stay tuned for more detailed findings in the upcoming publication.”

Quoting Giulia Marvaso’s post:

“So grateful to share my interview for UroToday + GU OncToday about our RADIOSA trial.

A huge opportunity to discuss our findings of a randomized phase II trial for oligorecurrent mHSPC: SBRT alone vs SBRT + 6 months ADT.